Drug General Information
Drug ID	D09SLU
Former ID	DIB014432
Drug Name	LG-101280
Synonyms	LG-101280; LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly
Indication	Arteriosclerosis [ICD9: 440; ICD10:I70]		Discontinued in Phase 1	[547284]
Company	Ligand Pharmaceuticals Inc
Structure		Download 2D MOL 3D MOL
Canonical SMILES	c1(ccc(cc1CC)OCC[C@@H](C)Oc1c(cc(cc1)CC)c1ncccc1)CCC(=O<br />)O
Target and Pathway
Target(s)	Peroxisome proliferator activated receptor alpha	Target Info	Modulator	[527514]
KEGG Pathway	PPAR signaling pathway
	cAMP signaling pathway
	Adipocytokine signaling pathway
	Glucagon signaling pathway
	Non-alcoholic fatty liver disease (NAFLD)
	Hepatitis C
Pathway Interaction Database	RXR and RAR heterodimerization with other nuclear receptor
Reactome	RORA activates gene expression
	BMAL1:CLOCK,NPAS2 activates circadian gene expression
	PPARA activates gene expression
	YAP1- and WWTR1 (TAZ)-stimulated gene expression
	Transcriptional activation of mitochondrial biogenesis
	Activation of gene expression by SREBF (SREBP)
	Transcriptional regulation of white adipocyte differentiation
	Nuclear Receptor transcription pathway
	Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
	Circadian Clock
WikiPathways	Nuclear Receptors in Lipid Metabolism and Toxicity
	Nuclear Receptors Meta-Pathway
	Estrogen Receptor Pathway
	PPAR Alpha Pathway
	Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
	Transcriptional Regulation of White Adipocyte Differentiation
	YAP1- and WWTR1 (TAZ)-stimulated gene expression
	Activation of Gene Expression by SREBP (SREBF)
	Adipogenesis
	SREBF and miR33 in cholesterol and lipid homeostasis
	Circadian Clock
	Nuclear Receptors
References
Ref 547284	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014823)
Ref 527514	A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol Endocrinol. 2005 Jun;19(6):1593-605. Epub 2005 Apr 14.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.